Amerstem, founded by a team of scientists from premier institutions like Johns Hopkins, Yale, and the University of Arizona, is a biotechnology company with a mission to innovate using their extensive expertise in molecular biology, regenerative medicine, and pharmaceuticals. The company has developed a sustainable and cost-effective cell culture core technology platform inspired by natural plant physiology and defense mechanisms. Their primary focus is on producing biologically active compounds, particularly Quillaja-derived saponin vaccine immunoadjuvants, to offer eco-friendly alternatives and preserve Quillaja saponaria trees.

Notable affiliations include professional experience at Johns Hopkins Hospital, Cedars-Sinai Medical Center, and Bayer Pharma. Amerstem has achieved significant milestones in creating a sustainable production method for phytoactives, contributing to both environmental conservation and medical advancements. Their innovative approach has positioned them as a key player in the biotech industry, providing critical solutions that blend scientific rigor with ecological responsibility.